Search results for " pediatria"

Follow up auxologico, BMI ed assetto endocrino in bambini con ipotiroidismo congenito: esperienza della clinica pediatrica di Palermo

2014

Deficit di G6PD: diagnosi fenotipica e genetica. Prevalenza e caratterizzazione molecolare delle varianti genetiche nella popolazione pediatrica sici…

2015

UNA NUOVA MUTAZIONE DEL GENE CREBBP IN UN BAMBINO CON SINDROME DI RUBINSTEIN TAYBI

2009

GH TREATMENT ADHERENCE IN CHILDHOOD AND ADOLESCENCE IMPROVES USING EASYPODTM DEVICE: DATA DEMONSTRATION IN AN ITALIAN CENTRE

2017

Objectives: Poor adherence to GH treatment is one of the pitfalls affecting the treatment efficacy. This study evaluates the GH treatment, using easypodTM in young patients over 6 months of therapy and describes the relationship between treatment efficacy and adherence. Methods: We collected the retrospective data registered in the electronic device easypodTM in 40 patients treated with GH. Number and doses of injection were used to calculate the percentage of treatment adherence. The inclusion criteria were: GH deficiency and the existence of one of the clinical condition in which GH is available: GHD, SGA, chronic renal failure, Turner syndrome. The GH efficacy was evaluated using the hei…

Impaired energy expenditure and physical activity in children affected by GH deficiency measured by SenseWear Armband: preliminary results.

2012

Background: Influence of growth hormone on energy expenditure and physical performance is clearly known. Objective and hypotheses: The aim of our study is to evaluate the energy expenditure (EE) during physical (PA) and sedentary activities (SA), in a group of children/adolescents affected by growth hormone deficiency (GHD) compared to healthy subjects, using an objective measure as SenseWear Armband (SWA-BodyMedia). Patients, methods and results: These preliminary data included 13 untreated, consecutive GHD children and adolescents (6 males) (GH peak 3 Mets) (1.5 ±0.8 vs 2.3±1 h/d), especially moderate (3-6 Mets)(1.4±0.8 vs 2.2±0.9 h/d; 5.8±3.1 vs 9.2±3.9% of daily hours) compared with hea…

EFFETTI AVVERSI NEI PAZIENTI IN TERAPIA CON GH IN UN CENTRO PEDIATRICO: DATI REAL LIFE

2019

OBIETTIVI Abbiamo analizzato la nostra casistica di pazienti in trattamento con GH: 145 pz (86M; 59F), età : 4-17 anni, al fine di valutare efficacia della terapia, eventuali eventi avversi, endocrinopatie insorte dopo l’inizio della terapia (tiroidite autoimmune; insufficienza surrenalica, etc) e/o iperglicemia o franco DM. METODI La casistica esaminata comprende: 6 pz con SHOX-D; 28 pz SGA; 5 con S. di Turner; 4 in terapia con GH per indicazioni diverse, previste dalla nota 39 (IRC, S. di Prader Willi). RISULTATI 3 pz (2 pz con S. di Turner; 1 pz con GHD) hanno manifestato, durante la terapia, tiroidite autoimmune e sono in terapia con L-tiroxina. 1 pz ha una diagnosi di iperinsulinismo c…

GROWTH HORMONE TREATMENT IN A PATIENT WITH LANGER MESOMELIC DYSPLASIA

2011

Gastroenterite Eosinofila ed asa triad.

2005

Ten-month follow-up of patients with covid-19 temporally related multi-system inflammatory syndrome in children: the experience of the children hospi…

2023

Abstract Background In Sicily, the first wave of COVID-19 showed a low epidemic impact in paediatric population, while the second and the third waves had a higher impact on clinical presentation of COVID-19 in children and a significantly higher severe outcome in patients with multisystem inflammatory syndrome in children (MIS-C), with a frequent life-threatening progression. Methods We describe a cohort of 22 Sicilian children (11 M; 11 F; age: 1.4–14 years), presenting with clinical features compatible with MIS-C. Patients with negative swab had a history of recent personal or parental infection. Results The following diagnostic criteria were detected: fever (100%); cheilitis and/or phary…

The "Honeymoon Phase" in Children with Type 1 Diabetes Mellitus (T1DM): Frequency, Duration and Predictive Factors at Onset

2012

Abstract: Aim of thè study was: to analyze thè epidemiological features of paediatric T1DM at onset and their relation to remission frequency and duration in thè first year of disease, to assess clinical effìcacy of Glucose Evaluation Trial REMission (GETREM) protocol in terms of induction and maintenance of thè "honeymoon phase" and to evaluate Insulin Dose-Adjusted A1C values at onset [IDAA1C = HbAlc% + (Insulin U/Kg/die x 4)] as a predictor of remission. 181 patients less than 15 years of age were admitted at our Department for T1DM onset and were treated according to GETREM protocol in thè years 2008-2011. The following data were recorded at onset: age, sex, modality of onset according …